Cases & Deals

Fonds InnoBio acts as selling shareholder in reverse merger of Millendo Therapeutics with OvaScience

Clients BPI France (Banque Publique d'Investissement)

Jones Day advised Fonds InnoBio, managed by Bpifrance, in connection with the reverse merger of Millendo Therapeutics, Inc., a privately-held, clinical-stage biopharmaceutical company focused on developing novel treatments for orphan endocrine diseases, with OvaScience, Inc. in an all-stock transaction, and concurrent equity financing.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.